Update in the Assessment and Management of Adult Growth Hormone Deficiency

Thursday, September 10, 2015; 7:00 9:30 PM EST
Intercontinental Miami Hotel, Grand Ballroom

This course is a live CME-certified ancillary symposium presented at the 67th Clinical Endocrinology Update (CEU) Meeting, held in Miami, Florida, September 1012, 2015. CEU 2015 ancillary symposia are developed through the Endocrine Society's Special Programs Committee (SPC).

This activity is supported by an educational grant from Novo Nordisk Inc.

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with growth hormone deficiency.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Interpret appropriate biochemical tests to diagnose GHD and assess treatment in young adult and adult patients
  • Use clinical observation, quality of life appraisal, and biochemical testing to reassess GH-deficient patients during transition period
  • Select and/or adjust GH therapy following assessment taking individual patient needs into consideration
  • Devise strategies to prevent and treat comorbidities in long-term management of GHD

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Quality Improvement and Healthcare Delivery
Growth Disorders
Neuroendocrinology and Pituitary
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.25 AMA PRA Category 1 Credits
  • 2.25 CME Certificate of Participation
Course opens: 
Course expires: 
Intercontinental Miami Hotel
Miami, FL
United States

Mark E. Molitch, MD – Program Director
Martha Leland Sherwin Professor of Endocrinology
Division of Endocrinology, Metabolism and Molecular Medicine
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Beverly M. K.  Biller, MD
Professor of Medicine
Harvard Medical School
Neuroendocrine Clinical Center
Massachusetts General Hospital
Boston, Massachusetts

Nelly Mauras, MD
Chief, Division of Endocrinology
Nemours Children’s Health System
Professor of Pediatrics
Mayo College of Medicine
Jacksonville, Florida


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Beverly M. K.  Biller, MD: Consultant, Pfizer, Versartis; Consultant and Research Funding, Novo Nordisk; Research Funding, Opko
Nelly Mauras, MD: Research Grant Support, Genentech, Pfizer, Prolor (Opko)
Mark E. Molitch, MD: Consultant, Corcept, Eli Lilly & Co., Pfizer; Consultant and Investigator, Ipsen Pharmaceuticals, Novartis Pharmaceuticals, Novo Nordisk Inc.

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: John Carmichael, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.25 AMA PRA Category 1 Credits
  • 2.25 CME Certificate of Participation